A study conducted in Cornell University, New York, USA, determined the basic oral pharmacokinetics, and assessed the safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).
At the first stage of the study a single-dose pharmacokinetics was performed using two doses of CBD oil 2 and 8mg/kg. Dogs receiving both doses had no obvious psychoactive side effect at any time point during the first stage. Pharmacokinetics results led to dosing during the second stage clinical trial at 2 mg/kg body weight every 12 h.
The clinical trial was a randomized placebo-controlled, veterinarian, and owner blinded, cross over. Dogs received CBD oil 2 mg/kg and placebo oil every 12 hours for one month with a two-week washout period. Clinically, CBD oil treatment in the dosage 2 mg/kg showed a significant decrease in pain and increase in activity in the time period that the received the treatment. No side effects
were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment.
Wakshlag, J.J., Frye, C.F., Gamble, L.J., Boesch, J., Schwark, W.S., Brown, H., Wolfe, L., Mann, S. and Berthelsen, E.S., 2018. “Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs.” Frontiers in Veterinary Science, 5, p.165.